Ajax Health

We welcome our lead investor Omega Funds and new investor Intuitive Ventures, and are grateful to our existing investors including founding investor Cleveland Clinic Innovations, Ajax Health, Broadview Ventures Inc, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, CincyTech and our unnamed strategic investor. Saoussen Ben Halima, PhD Claudio Nessi Marla Jalbut, MD, MBA Murielle Thinard McLane Jotthe Kannappan Vijay Rajasekhar, MD, MBA Vivian Emmely Golfin, MD JD Friedland Zach Eisen Duke Rohlen Aftab Kherani Doug Koo Shane Kreidel Daniel Gottlieb Maria Berkman, MD Anthony Natale, M.D. Eric S. Tatyana Hower Steph Ison Samuel Lee, MD, MBA Ashley Keating Anthony Caparso John Sam Bhavesh Patel Rabih Nassif Andrew Wu

How much weight should be placed on intellectual property protection for Medtech startups? While patents often serve as a cornerstone for many startups, David Beylik’s perspective might surprise you. In this clip, David Beylik says that IP isn't always the primary focus for them. Regulatory approval, clinical data, and manufacturing expertise often carry more weight in terms of a company’s defensibility and long-term success. So, does that mean IP isn’t important? Not exactly. While IP might not always be a deal-breaker or maker, there are times when it’s critical and can halt an investment in its tracks. In other words, while IP might not always be at the forefront of an investment decision, when it matters, it really matters. For innovators, this means that building a strong IP portfolio should be part of a broader strategy that includes securing regulatory approvals and developing robust operational capabilities. Tune into the full LSI USA ‘24 panel, “IP: Friend or Foe in Building Medtech Ventures?” to hear more from the panelists on this nuanced discussion. Hear from: • Irfan Lateef (Moderator) — Knobbe Martens • Leah Brownlee — Lazurite • Sabing Lee — Knobbe Martens • David Beylik — Ajax Health

This HBR article by Duke Rohlen, Regina Herzlinger, Ben Creo and Will Kynes is a must read for everyone who is looking for new strategies to foster innovation within a corporate environment. The Growth Driver Models maximises alignment with strategy, minimises cost and reduces risks, compared to internal innovation or acquisition.

We are thrilled to welcome Duke Rohlen as a Keynote Speaker at #LSIEurope24 in Sintra, Portugal. Duke Rohlen is a serial entrepreneur and currently serves as CEO and Managing Director of Ajax Health, a turnkey growth solution for commercial-stage Medtech companies. Ajax Health specializes in developing comprehensive product portfolios that can be seamlessly integrated into a commercial framework. Prior to Ajax Health, Duke co-founded and served as the Chairman and CEO of EPIX Therapeutics (acquired by Medtronic in 2019), served as co-founder and CEO of Spirox (acquired by Entellus in 2017), co-founded and served as CEO of CV Ingenuity (acquired by Covidien in 2013), served in a variety of roles at FoxHollow Technologies before being named President where he led the sale of the company to ev3 (now Medtronic) in 2008. The Keynote will be moderated by Mano Iyer, Partner in the Sofinnova Partners MD Start Strategy and Founder of Recor Medical. Mano was also among the co-founders of the original MD Start team that incubated companies including CorWave and LimFlow. Duke’s Keynote will be based on his recently published thesis, "The Middle Path to Innovation," published in the Harvard Business Review. He will discuss strategies for developing high-growth products in slow-growth companies and present the growth driver model—a framework that partners corporations with external investors to identify and develop innovation opportunities, drawing on corporate resources and talent and externally recruited entrepreneurs. This Keynote will take place on September 18th (Day 2) at LSI Europe ‘24 in Sintra, Portugal. Want to watch this Keynote live? Join nearly 1,000 global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply today while space is still available.

I’m fired up on the entire Ajax Health Ecosystem for creating, optimizing and institutionalizing the Ajax Growth Driver Model to drive medical device innovation. The attached Harvard Business Review article does a nice job of providing additional detail behind the model’s construct. Our model is powerful, high impact – a multifaceted alignment of activities, people, capital, strategy, development, and operating partnership. And it works, well. What we have implemented for Cordis with Cordis-X, and for Hologic, Inc. with Maverix, is what we will implement for any large strategic that is need of turn-key, off-balance sheet, turbo-charged growth. #HBR #GrowthDriver #Innovation

We are pleased to announce the addition of Dr. Matthew Lungren MD MPH, Chief Data Science Officer for Microsoft Health & Life Sciences, to our Board of Directors. Lungren will bring his expertise translating cutting-edge AI technology into valuable healthcare applications to our efforts to transform the diagnosis and treatment of atrial arrhythmias.   Join us at #HRS2024 to learn more about how the Cortex OptiMap™ System helps physicians See What Matters (Rhythm Theater 1 on Saturday, May 18 at 9:15 am in the Exhibit Hall of the Boston Convention and Exhibition Center).   To learn more, visit us at booth 869 or click here: www.CortexEP.com   #EPeeps, #AFablation #AF #Afib

This year at #HRS2024, meet the OptiMap™ System, a 510(k) cleared electrographic flow (EGF) mapping solution designed with AI, enabling physicians to See What Matters. Hear expert faculty present how they have used the OptiMap System in cases with complex and challenging AF patients in our Rhythm Theater on Sat, May 18, 9:15–10:00 am. Drop by booth 869 to see the OptiMap System. Learn more about how the system is being used for phenotyping, prognosis, improved outcomes, and recurrence prediction in the five abstracts and presentations by leading experts: Dr. Ilana Kutinsky, Dr. Kent Nilsson, Jr., Dr. Tamas Szili-Torok, Dr. Michael Mangrum, and Dr. Vivek Reddy. For more, visit our website: www.cortexep.com #Epeeps #EP #AF #AFib

Duke Rohlen talking to the Vanderbilt Heart Failure/Transplant group about teamwork, goals, dedication, discipline, leadership and more. We all can benefit from learning from the best in other fields. Phenomenal talk and discussion!

The multi-national RESOLVE-AF trial enrolled its first patient in the EU today as Dr. Max Liebregts and Dr. Lucas Boersma completed the first case at St. Antonius Hospital Nieuwegein, The Netherlands. Boersma, the European PI for the international trial said, “I’m excited to participate in this study to evaluate Cortex’s EGF mapping as a promising approach to identify extra-pulmonary vein EGF sources and their phenotypes." RESOLVE-AF is a prospective, international, multi-center trial to evaluate the use of the OptiMap™ System and OptiMap™ Catheter to identify extra-pulmonary vein EGF sources and their phenotypes. #EPeeps, #AFablation

"After launching late last year, the lung cancer-focused startup Maverix Medical is reaching for the sky with the acquisition of diagnostic developer Cirrus Bio." --Conor Hale, Fierce Biotech